Parthenogenetic development of domestic cat oocytes treated with ionomycin, cycloheximide, roscovitine and strontium.
The objective was to evaluate the parthenogenetic activation of domestic cat oocytes. Cumulus-oocyte complexes matured for 36 h were subjected to three protocols of parthenogenetic activation: Group 1 - ionomycin + cycloheximide; Group 2 - ionomycin + roscovitine; and Group 3 - ionomycin + strontium. As a control, a fourth group of oocytes were cultured in the absence of any activation agent. In all groups, embryos were cultured in SOFaa for 72 h after activation and evaluated for activation rate, cleavage, and embryonic development using Hoechst33342. There were no significant differences among the three treated groups for rates of activated oocytes (70.1 +/- 4.3, 75.5 +/- 4.7, and 61.9 +/- 7.2%, for Treatments 1, 2, and 3 respectively; mean +/- SEM), or cleavage (48.1 +/- 5.9, 47.4 +/- 3.8, and 33.3 +/- 6.8%). However, activation and cleavage rates were higher (P < 0.05) than those in the control group (35.5 +/- 6.4 and 11.8 +/- 4.0%). There were no significant differences among treatment groups for proportion of embryos with 2-10 cells, 10-16 cells, and morulas. In the Control group, the embryo production rate was lower (P < 0.05), although the activation rate was high. The authors concluded that all three treatments effectively induced parthenogenetic activation of domestic cat oocytes. However, to optimize the use of strontium and roscovitine, a dose response and the effect of the presence of Ca(++) in the medium requires further study.
Rascado
T da Silva
Tda S
Department of Animal Reproduction and Veterinary Radiology, Faculty of Veterinary Medicine and Animal Science, Univ. Estadual Paulista-FMVZ, UNESP, Botucatu, SP, Brazil.
Martins
L Rigatto
LR
Minto
B Watanabe
BW
de Sá Lorena
S E R
SE
Landim-Alvarenga
F da Cruz
Fda C
D000818:Animals; D002415:Cats / Q000196:embryology*; D003470:Culture Media; D003513:Cycloheximide / Q000494:pharmacology*; D046149:Embryo Culture Techniques; D005260:Female; D015759:Ionomycin / Q000494:pharmacology*; D009865:Oocytes / Q000166:cytology / Q000187:drug effects* / Q000254:growth & development; D010312:Parthenogenesis / Q000187:drug effects*; D011687:Purines / Q000494:pharmacology*; D000077546:Roscovitine; D013324:Strontium / Q000494:pharmacology*
D003470:Culture Media; D011687:Purines; D000077546:Roscovitine; D015759:Ionomycin; D003513:Cycloheximide; D013324:Strontium